Technology
Health
Biotechnology

Chiasma

$5.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.17 (-18.87%) Today
+$0.17 (3.38%) After Hours

Why Robinhood?

You can buy or sell Chiasma and other stocks, options, ETFs, and crypto commission-free!

About

Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. Read More The firm's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Waltham, MA.

Employees
18
Headquarters
Waltham, Massachusetts
Founded
2001
Market Cap
151.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
69.53K
High Today
$6.23
Low Today
$4.67
Open Price
$6.21
Volume
206.19K
52 Week High
$7.19
52 Week Low
$1.20

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2015 IPO
US

News

Markets Insider3h

Chiasma Announces Three Poster Presentations at ENDO 2019

WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Society’s Annual Meeting and Expo, which is being held March 23-26 in New Orleans. William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs, said, “We are pleased to present three posters at ENDO t...

11
MarketBeatMar 3

Stock Price, News, & Analysis for Chiasma

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc...

31

Earnings

-$0.36
-$0.31
-$0.27
-$0.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.32 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.